이상지혈증 환자군의 심혈관 질환 위험 등급의 분류에서 LDL콜레스테롤 측정치 혹은 계산치보다 Non-HDL 콜레스테롤이 더 정확하다
Non–HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Background: Our objective was to evaluate the accuracy of cardiovascular disease (CVD) risk score classification by direct LDL cholesterol (dLDL-C), calculated LDL cholesterol (cLDL-C), and non–HDL cholesterol (non–HDL-C) compared to classification by reference measurement procedures (RMPs) performed at the CDC. Methods: Weexamined 175 individuals, including 138 with CVD or conditions that may affect LDL-C measurement. dLDL-C measurements were performed using Denka, Kyowa, Sekisui, Serotec, Sysmex, UMA, and Wako reagents. cLDL-C was calculated by the Friedewald equation, using each manufacturer’s direct HDL-C assay measurements, and total cholesterol and triglyceride measurements by Roche and Siemens (Advia) assays,respectively. Results: For participants with triglycerides <2.26 mmol/L (<200 mg/dL), the overall misclassification rate for the CVD risk score ranged from 5% to 17% for cLDL-C methods and 8% to 26% for dLDL-C methods when compared to the RMP. Only Wako dLDL-C had fewer misclassifications than its corresponding cLDL-C method (8% vs 17%; P <0.05). Non–HDL-C assays misclassified fewer patients than dLDL-C for 4 of 8 methods (P <0.05). For participants with triglycerides ≥2.26 mmol/L (≥200 mg/dL) and <4.52 mmol/L (<400 mg/dL), dLDL-C methods, in general, performed better than cLDL-C methods, and non–HDL-C methods showed better correspondence to the RMP for CVD risk score than either dLDL-C or cLDL-C methods. Conclusions: Except for hypertriglyceridemic individuals, 7 of 8 dLDL-C methods failed to show improved CVD risk score classification over the corresponding cLDL-C methods. Non–HDL-C showed overall the best concordance with the RMP for CVD risk score classification of both normal and hypertriglyceridemic individuals.
Abstract
Background: Our objective was to evaluate the accuracy of cardiovascular disease (CVD) risk score classification by direct LDL cholesterol (dLDL-C), calculated LDL cholesterol (cLDL-C), and non–HDL cholesterol (non–HDL-C) compared to classification by reference measurement procedures (RMPs) performed at the CDC. Methods: Weexamined 175 individuals, including 138 with CVD or conditions that may affect LDL-C measurement. dLDL-C measurements were performed using Denka, Kyowa, Sekisui, Serotec, Sysmex, UMA, and Wako reagents. cLDL-C was calculated by the Friedewald equation, using each manufacturer’s direct HDL-C assay measurements, and total cholesterol and triglyceride measurements by Roche and Siemens (Advia) assays,respectively. Results: For participants with triglycerides <2.26 mmol/L (<200 mg/dL), the overall misclassification rate for the CVD risk score ranged from 5% to 17% for cLDL-C methods and 8% to 26% for dLDL-C methods when compared to the RMP. Only Wako dLDL-C had fewer misclassifications than its corresponding cLDL-C method (8% vs 17%; P <0.05). Non–HDL-C assays misclassified fewer patients than dLDL-C for 4 of 8 methods (P <0.05). For participants with triglycerides ≥2.26 mmol/L (≥200 mg/dL) and <4.52 mmol/L (<400 mg/dL), dLDL-C methods, in general, performed better than cLDL-C methods, and non–HDL-C methods showed better correspondence to the RMP for CVD risk score than either dLDL-C or cLDL-C methods. Conclusions: Except for hypertriglyceridemic individuals, 7 of 8 dLDL-C methods failed to show improved CVD risk score classification over the corresponding cLDL-C methods. Non–HDL-C showed overall the best concordance with the RMP for CVD risk score classification of both normal and hypertriglyceridemic individuals.
참고문헌 (37)
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP), "Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- Nauck M, "Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation", Clin Chem, 48, pp.236~254 (2002)
- Nauck M, "Handbook of lipoprotein testing", pp.227~230 (2000), AACC Press
- Gordon T, "Lipoproteins, cardiovascular disease, and death. The Framingham study", Arch Intern Med, 141, pp.1128~1131 (1981)
- Castelli WP, "HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study", Circulation, 55, pp.767~772 (1977)
- Myers GL, "A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements", Clin Chem, 46, pp.1762~1772 (2000)
- Friedewald WT, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge", Clin Chem, 18, pp.499~502 (1972)
- Schectman G, "Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations", Clin Chem, 42, pp.732~737 (1996)
- Miller WG, "Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures", Clin Chem, 56, pp.977~986 (2010)
- Sahu S, "Comparison of two methods of estimation of low density lipoprotein cholesterol, the direct versus Friedewald estimation", Indian J Clin Biochem, 20, pp.54~61 (2005)
- Miller WG, "Performance of four homogeneous direct methods for LDL-cholesterol", Clin Chem, 48, pp.489~498 (2002)
- Warnick GR, "Standardization of measurements for cholesterol, triglycerides, and major lipoproteins", Lab Med, 39, pp.481~490 (2008)
- Lachenbruch PA, "Assessing screening tests: extensions of McNemar’s test", Stat Med, 17, pp.2207~2217 (1998)
- Ricos C, "Current databases on biological variation: pros, cons and progress", Scand J Clin Lab Invest, 59, pp.491~500 (1999)
- Cohn JS, "Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states", Clin Chem, 34, pp.2456~2459 (1988)
- Rifai N, "Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements", Ann Clin Biochem, 27, pp.489~493 (1990)
- Mora S, "Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events", Circulation, 118, pp.993~1001 (2008)
- Mora S, "Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women", Clin Chem, 55, pp.888~894 (2009)
- Yu HH, "Evaluation and clinical application of a direct low-density lipoprotein cholesterol assay in normolipidemic and hyperlipidemic adults", Am J Cardiol, 80, pp.1295~1299 (1997)
- Cohn JS, "Postprandial plasma lipoprotein changes in human subjects of different ages", J Lipid Res, 29, pp.469~479 (1988)
- Lund SS, "Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus", Scand J Clin Lab Invest, 68, pp.628~640 (2008)
- Liu J, "Joint distribution of Non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes", Diabetes Care, 28, pp.1916~1921 (2005)
- Lu W, "Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study", Diabetes Care, 26, pp.16~23 (2003)
- Jiang R, "Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes", Diabetes Care, 27, pp.1991~1997 (2004)
- Ingelsson E, "Clinical utility of different lipid measures for prediction of coronary heart disease in men and women", JAMA, 298, pp.776~785 (2007)
- Ridker PM, "Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women", JAMA, 294, pp.326~333 (2005)
- Bittner V, "Nonhigh- density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)", Circulation, 106, pp.2537~2542 (2002)
- Cui Y, "Non-highdensity lipoprotein cholesterol level as a predictor of cardiovascular disease mortality", Arch Intern Med, 161, pp.1413~1419 (2001)
- Miller M, "Relative atherogenicity and predictive value of non-highdensity lipoprotein cholesterol for coronary heart disease", Am J Cardiol, 101, pp.1003~1008 (2008)
- Liu J, "Nonhigh-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease", Am J Cardiol, 98, pp.1363~1368 (2006)
- Di Angelantonio E, "Major lipids, apolipoproteins, and risk of vascular disease", JAMA, 302, pp.1993~2000 (2009)
- Brunzell JD, "Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation", Diabetes Care, 31, pp.811~822 (2008)
- Kukita H, "Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease", Atherosclerosis, 51, pp.261~267 (1984)
- Maciejko JJ, "Apolipoprotein A-I as a marker of angiographically assessed coronaryartery disease", N Engl J Med, 309, pp.385~389 (1983)
- van der Steeg WA, "Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk", Ann Intern Med, 146, pp.640~648 (2007)
- Hackam DG, "Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence", JAMA, 290, pp.932~940 (2003)
- Carmena R, "Atherogenic lipoprotein particles in atherosclerosis", Circulation, 109(1), pp.2~7 (2004)